News | November 26, 2007

Gamma Medica-Ideas, Mayo Clinic Collaborate on Breast Cancer Research Project

November 27, 2007 - Gamma Medica-Ideas Inc. has announced its collaboration with Mayo Clinic on a new breast cancer research project, the primary goal of which is to document the advantages of using GM-I’s LumaGEM dual-headed Molecular Breast Imaging (MBI) technology for the early detection, diagnosis and treatment of breast cancer. The project is funded by a grant from the National Cancer Institute.

Researchers also hope to prove LumaGEM’s capabilities in breast cancer staging, therapy planning, monitoring and follow-up. The two-phase collaborative project will enroll approximately 500 patients. Project researchers will use the LumaGEM MBI imager to noninvasively define the characteristics of a patient’s breast cancer cells at a molecular level by using established and novel radioactive markers. During Phase I, a dual-headed CZT LumaGEM will be installed at Mayo Clinic. In phase II, an additional LumaGEM system will be installed at Cedars-Sinai (Los Angeles, CA). Dr. Iraj Khalkhali (Los Angeles, CA) will take delivery of yet another LumaGEM. The patient studies will be conducted with all three systems to compare the diagnostic capabilities of this device to Magnetic Resonance Imaging (MRI). Mayo Clinic will subsequently evaluate promising new radiopharmaceuticals for the detection of breast cancer. Finally, Cedars-Sinai will conduct a study demonstrating the dual-isotope capability of this system and compare the diagnostic potential of both isotopes.

Gamma Medica-Ideas’ LumaGEM is a dedicated gamma camera used for diagnostic imaging, including MBI. The LumaGEM system features fully solid state digital detection utilizing eV Products Cadmium Zinc Telluride (CZT) to provide superior resolution compared with the conventional scintillation camera technology traditionally used in gamma cameras, the company says. It also reportedly allows minimal dead space at the edges of the image, permitting the closest access to the chest wall.

For more information:

Related Content

A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.